Neonatology pp 364-368 | Cite as

Developmental Pharmacology and Therapeutics

  • Erika Crane
  • Victoria Tutag Lehr
  • Merene Mathew
  • Jacob V. Aranda


Developmental pharmacology and therapeutics is a broad field that includes the study of drugs during growth and development and the effect of these drugs on development itself. Development is a continuum that includes periods of conception, fetal stages and the neonatal and childhood phases of development. This chapter focuses on pharmacology and therapeutics in the newborn infant.


Therapeutic Drug Monitoring Peak Serum Concentration Total Body Surface Area Therapeutic Serum Concentration Minimal Inhibitory Concentration Ratio 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Clark RH, Bloom BT, Spitzer AR, Gerstmann DR (2006) Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 117: 1979–1987PubMedCrossRefGoogle Scholar
  2. 2.
    Conroy S, McIntyre JM, Choonara I (1999) Unlicensed and off-label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 80: F142–F144PubMedCrossRefGoogle Scholar
  3. 3.
    Aranda JV, Cohen S, Neims AH (1976) Drug utilization in a newborn intensive care unit. J Pediatr 89: 315–317PubMedCrossRefGoogle Scholar
  4. 4.
    American Academy of Pediatrics, Committee on Drugs (2002) Uses of drugs not described in the package insert (off-label uses). Pediatrics 110: 181–183CrossRefGoogle Scholar
  5. 5.
    t Jong GW, Vulto AG, de Hoog M et al (2000) Unapproved and offlabel use of drugs in a children’s hospital. N Engl J Med 343: 1125PubMedCrossRefGoogle Scholar
  6. 6.
    Avenel S, Bomkratz A, Dassieu G et al (2000) The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr 7: 143–147PubMedCrossRefGoogle Scholar
  7. 7.
    Guerrini R (2006) Valproate as a mainstay of therapy for paediatric epilepsy. Paediatr Drugs 8113–129Google Scholar
  8. 8.
    Heresi GP, Gerstmann DR, Reed MD et al (2006) The pharmaco- kinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 25: 1110–1115PubMedCrossRefGoogle Scholar
  9. 9.
    Hope WW, Mickiene D, Petraitis V et al (2008) The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 197: 163–171PubMedCrossRefGoogle Scholar
  10. 10.
    Benjamin DK Jr, Smith PB, Arrieta A (2010) Safety and pharma-cokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 87: 93–99PubMedCrossRefGoogle Scholar
  11. 11.
    Taketomo CK, Hodding JH, Kraus DM (2008) Pediatric Dosage Handbook, 15th edn. Lexicomp, Hudson, Ohio, pp 1765–1768Google Scholar
  12. 12.
    Kearns GL, Abdel-Rahman SM, Alander SW et al (2003) Developmental pharmacology - drug disposition, action and therapy in infants and children. N Engl J Med 349: 1157–1167PubMedCrossRefGoogle Scholar
  13. 13.
    Koren G (1997) Therapeutic drug monitoring principles in the neonate. Clin Chem 43: 222–227PubMedGoogle Scholar
  14. 14.
    Yaffe SJ, Aranda JV (2004) Neonatal and pediatric pharmacology, 3rd edn. Lippincott, Williams & Wilkins, PhiladelphiaGoogle Scholar
  15. 15.
    Rutter N (1996) The immature skin. Eur J Pediatr 155: S18–S20PubMedCrossRefGoogle Scholar
  16. 16.
    Hoath SB, Narendran V (2000) Adhesives and emollients in the preterm infant. Semin Neonatol 5: 289–296PubMedCrossRefGoogle Scholar
  17. 17.
    Campbell JM, Banta-Wright SA (2000) Neonatal skin disorders: a review of selected dermatologic abnormalities. J Perinatal Neonatal Nurs 14: 63–83Google Scholar
  18. 18.
    Shwayder T, Akland T (2006) Neonatal skin barrier: structure, function, and disorders. Dermatologic Ther 18: 87–103CrossRefGoogle Scholar
  19. 19.
    Blake MJ, Castro L, Leeder JS, Kearns GL (2005) Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 10: 123–138PubMedCrossRefGoogle Scholar
  20. 20.
    Pinto N, Halachmi N, Zulfikarali V et al (2005) Ontogeny of renal P-glycoprotein expression in mice: correlation with digoxin renal clearance. Pediatr Res 58: 1284–1289PubMedCrossRefGoogle Scholar
  21. 21.
    Marquet P (1999) Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects. Acta Clin Belg Supp 1: 1–12Google Scholar
  22. 22.
    Von Winckelmann SL, Spriet I, Willems L (2008) Therapeutic monitoring of phenytoin in critically ill patients. Pharmacotherapy 28: 1391–1400CrossRefGoogle Scholar
  23. 23.
    Soldin OP, Soldin JP (2002) Review: Therapeutic drug monitoring in pediatrics. Ther Drug Monit 24: 1–8Google Scholar
  24. 24.
    Johannessen SI, Tomson I (2006) Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Phar- macokinet 45: 1061–1075CrossRefGoogle Scholar
  25. 25.
    Boreus LO (1989) The role of therapeutic drug monitoring in children. Clin Pharmacokinet 17 (Suppl 1): 4–12PubMedCrossRefGoogle Scholar
  26. 26.
    Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN (2006) Guidelines on paediatric dosing on the basis of develop-mental physiology and pharmacokinetic considerations. Clin Phar- macokinet 45: 1077–1097CrossRefGoogle Scholar
  27. 27.
    Begg EJ, Barclay ML, Kirkpatrick CJ (1999) The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 47: 23–30PubMedCrossRefGoogle Scholar
  28. 28.
    Nestas E, Bangstad HJ, Sandvik L, Wathane KO (2005) Amino- glycoside extended interval dosing in neonates is safe and effective: a meta-analysis. Arch Dis Child Fetal Neonatal Ed 90: F294–F300CrossRefGoogle Scholar
  29. 29.
    de Hoog M, Mouton JW, Schoemaker RC et al (2002) Extended- interval dosing of tobramycin in neonates: Implications for therapeutic monitoring. Clin Pharmacol Ther 71: 349–358PubMedCrossRefGoogle Scholar
  30. 30.
    Aust G (2001) Vestibulotoxicity and otoxicity of gentamicin in newborns at risk. Int Tinnitis J 7: 27–29Google Scholar
  31. 31.
    Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infectious Dis 155: 93–99CrossRefGoogle Scholar
  32. 32.
    de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN (1997) Tobramycin population pharmacokinetics in neonates. Clin Pharmacol Ther 62: 392–399PubMedCrossRefGoogle Scholar
  33. 33.
    de Hoog M, Mouton JW, van den Anker JN (2004) Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet 43: 417–440PubMedCrossRefGoogle Scholar
  34. 34.
    Grohskopf LA, Huskins WC, Sinkowitz-Cochran RL et al (2005) Use of antimicrobial agents in United States neonatal and pediatric intensive care patients. Pediatr Infect Dis J 24: 766–773PubMedCrossRefGoogle Scholar
  35. 35.
    Bizzarro MJ Gallagher PG (2007) Antibiotic-resistant organisms in the neonatal intensive care unit. Semin Perinatol 31: 26–32PubMedCrossRefGoogle Scholar
  36. 36.
    Capparelli EV, Lane JR, Romanowski GL et al (2001) The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 41: 927–934PubMedCrossRefGoogle Scholar
  37. 37.
    Guilano C, Haase KK, Hall R (2010) Use of vanco PK-PD properties in the treatment of MRSA infections in newborns. Expert Rev Anti Ther 8: 95–106CrossRefGoogle Scholar
  38. 38.
    Christensen ML, Helms RA, Chesney RW (1999) Is pediatric labeling really necessary? Pediatrics 104: 593–597PubMedGoogle Scholar
  39. 39.
    Hutchinson DJ, Liou Y, Best R, Zhao F (2010) Stability of extemporaneously prepared rufinamide oral suspensions. Ann Pharma- cother 44: 462–465CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  • Erika Crane
  • Victoria Tutag Lehr
  • Merene Mathew
  • Jacob V. Aranda
    • 1
  1. 1.Division of Neonatology and Perinatal Translational Research LaboratoryState University of New YorkBrooklynUSA

Personalised recommendations